Dolutegravir / lamivudine for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults and adolescents over 12 years of age

Document first published:
Page updated:
Topic:
Publication type:

Dolutegravir/lamivudine for the treatment of HIV infected adults and adolescents >12 years of age is recommended to be available as a treatment option through routine commissioning within the criteria set out in this document.

Document

Document

Document

CPAG Summary Report

CPAG Summary Report

  • PDF
  • 90 KB
  • 8 pages